Kevin Bell has a diverse practice representing national and multi-national corporations, universities and organizations in complex patent and trade secret litigation, International Trade Commission (ITC) investigations, trademark and unfair competition litigation, patent false marking litigation as well as settlement and license negotiations involving significant intellectual property portfolios. Mr. Bell works with members of Patton Boggs’ corporate and regulatory practices on intellectual property matters that arise in corporate mergers, acquisitions and other due diligence transactions. In addition, Mr. Bell also practices in the area of sports and entertainment law.
Mr. Bell handles matters relating to complex patent litigation for numerous domestic and multi-national clients involving large intellectual property portfolios and multiple foreign jurisdictions. He has been active in multi-district litigation and represents companies in a broad range of technologies that include chemical, biotech, pharmaceutical, medical device, dietary supplement, software, semi-conductor and computer science related matters before federal courts throughout the country, the ITC, the appellate court system and various alternative dispute resolution forums. In his patent litigation practice, Mr. Bell has successfully developed and implemented novel patent damages and economic theories to obtain substantial monetary damages awards on behalf of his clients. Mr. Bell also has extensive experience in assisting clients in creatively and successfully negotiating and licensing intellectual property in several industry sectors.
Mr. Bell has also developed a substantial practice defending companies accused of violating the False Marketing Statute (35 U.S.C. § 292) in qui tam actions. Mr. Bell was involved in the precedent setting case addressing false marking, Clontech Labs. v. Invitrogen Corp. (D. Del.). Since that time, he has represented and advised numerous companies on issues regarding false marking, including acting as litigation counsel and also providing guidance to companies on best practices to avoid liability.
Mr. Bell also maintains a practice in the area of sports and entertainment law. He represents individual and corporate clients on a broad range of legal matters, including negotiating contracts, endorsements, advertising and merchandising agreements, media rights and protection of intellectual property relating to sports and celebrity clients. Mr. Bell also assists certain clients with career management and general business matters.
- Becton, Dickinson and Company v. Tyco Healthcare LP, Civil Action No. 02-1694 GMS, U.S. District Court of Delaware
- Clontech Laboratories, Inc. v. Invitrogen Corporation, 263 F. Supp.2d 780 (D. Del. 2003)
- Biacore AB v. Thermo BioAnalysis, Inc., 79 F.Supp.2d 422 (D. Del. 1999)
- Ajinomoto Co. v. Archer-Daniel-Midland Co., 228 F.3d 1338 (Fed. Cir. 2000), aff’d and 1998 U.S. Dist. LEXIS 3833 (D. Del. 1998)
- Greatbatch, Inc.
- Howard Foundation Holdings, LLC
- The Original Creatine Patent Co., Ltd.
- Natural Alternatives International, Inc.
- KGK Synergize, Inc.
American Bar Association (ABA) – ABA Sections – Litigation and Intellectual Property; ABA Forum – Entertainment and Sports Law International Trade Commission Trial Lawyers Association (ITCTLA) American Association of Justice (formerly American Trial Lawyers Association) Maryland Bar Association Transportation Lawyers Association (TLA) Sports Lawyers Association (SLA) International Association of Sports Law (IASL) Japan-America Society of Hawaii